Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients

International Journal of Antimicrobial Agents

Volumn 37, Issue 4, 2011, Pages 309-315

  Fricks Lima, J ^a   Hendrickson, C M ^a   Allgaier, M ^a   Zhuo, H ^a   Wiener Kronish, J P ^b   Lynch, S V ^a   Yang, K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial resistance; Bacterial biofilm; Cystic fibrosis; Mechanical ventilation; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOFILM; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; LUNG INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; RESPIRATION, ARTIFICIAL;

EID: 79952818334     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.12.017     Document Type: Article

References (41)

1. Parsek MR, Greenberg EP. Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol 2005;13:27-33. (Pubitemid 40082394)
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22. (Pubitemid 29289651)
3. El-Azizi M, Rao S, Kanchanapoom T, Khardori N. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 2005;4:2.
4. Lynch SV, Dixon L, Benoit MR, Brodie EL, Keyhan M, Hu P, et al. Role of the rapA gene in controlling antibiotic resistance of Escherichia coli biofilms. Antimicrob Agents Chemother 2007;51:3650-8. (Pubitemid 47519356)
5. Sottile FD, Marrie TJ, Prough DS, Hobgood CD, Gower DJ, Webb LX, et al. Nosocomial pulmonary infection: possible etiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986;14:265-70. (Pubitemid 16102040)
6. Feldman C, Kassel M, Cantrell J, Kaka S, Morar R, Goolam Mahomed A, et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J 1999;13:546-51. (Pubitemid 29180163)
7. Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 1999;25:1072-6. (Pubitemid 29525061)
8. Kobayashi H, Kobayashi O, Kawai S. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract. J Infect Chemother 2009;15:125-42.
9. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 2009;43:28-35.
10. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007;35:1888-95. (Pubitemid 47220363)
11. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:1129-35. (Pubitemid 26126878)
12. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998;30:295-304. (Pubitemid 28480181)
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Wayne, PA: CLSI; 2009 [Document M100-S-19].
14. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004;42:1915-22. (Pubitemid 38637802)
15. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
16. Craven DE, Steger KA. Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin Respir Infect 1996;11:32-53.
17. Deligianni E, Pattison S, Berrar D, Ternan NG, Haylock RW, Moore JE, et al. Pseudomonas aeruginosa cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro. BMC Microbiol 2010;10:38.
18. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009;54:628-40.
19. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005;171:1209-23. (Pubitemid 40740727)
20. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 2004;48:1175-87. (Pubitemid 38405471)
21. Nucleo E, Steffanoni L, Fugazza G, Migliavacca R, Giacobone E, Navarra A, et al. Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol 2009;9:270.
22. Elliott D, Burns JL, Hoffman LR. Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2010;54:3024-6.
23. Fonseca AP, Extremina C, Fonseca AF, Sousa JC. Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa. J MedMicrobiol 2004;53:903-10. (Pubitemid 39238397)
24. Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008;300:805-13.
25. Kolobow T, Berra L, Li Bassi G, Curto F. Novel system for complete removal of secretions within the endotracheal tube: the Mucus Shaver. Anesthesiology 2005;102:1063-5. (Pubitemid 40586550)
26. Berra L, Curto F, Li Bassi G, Laquerriere P, Baccarelli A, Kolobow T. Antibacterial-coated tracheal tubes cleaned with the Mucus Shaver: a novel method to retain long-term bactericidal activity of coated tracheal tubes. Intensive Care Med 2006;32:888-93. (Pubitemid 43781371)
27. Lorente L, Blot S, Rello J. New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2010;182:870-6.
28. Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, et al. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 2002;28:426-31. (Pubitemid 34328026)
29. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: amatched case-control study. Clin Infect Dis 2010;51:1238-44.
30. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010;16:1230-6.
31. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-7. (Pubitemid 41170367)
32. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008;102:407-12. (Pubitemid 351179979)
33. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
34. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26:31-9. (Pubitemid 28028437)
35. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-26. (Pubitemid 34754166)
36. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10:R123.
37. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gramnegative bacteria. J Antimicrob Chemother 2010;65:2645-9.
38. Keays T, Ferris W, Vandemheen KL, Chan F, Yeung SW, Mah TF, et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009;8:122-7.
39. Use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy. Bethesda, MD: ClinicalTrials.gov. Identifier NCT00786513. http://www.clinicaltrials.gov/ct2/show/NCT00786513 [accessed 8 November 2010].
40. Standard vs. biofilm susceptibility testing in cystic fibrosis (CF). Bethesda, MD: ClinicalTrials.gov. Identifier NCT00153634. http://www. clinicaltrials. gov/ct2/show/NCT00153634 [accessed 8 November 2010].
41. Tre-Hardy M, Mace C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ. Effect of antibiotic co-administrationonyoung and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Int J Antimicrob Agents 2009;33:40-5.